Edwards Lifesciences price target raised to $107 from $103 at Jefferies

Jefferies analyst Matthew Taylor raised the firm’s price target on Edwards Lifesciences to $107 from $103 and keeps a Buy rating on the shares. The firm’s model and data, which the firm says “has a strong track record of calling the quarters,” gives it confidence in Q2 results and Jefferies likes the setup for the stock through the year and into 2024, the analyst tells investors in a Q2 earnings preview note.